Citadel Advisors - TETRAPHASE PHARMACEUTICALS I ownership

TETRAPHASE PHARMACEUTICALS I's ticker is TTPHXXXX and the CUSIP is 88165N105. A total of 68 filers reported holding TETRAPHASE PHARMACEUTICALS I in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
Citadel Advisors ownership history of TETRAPHASE PHARMACEUTICALS I
ValueSharesWeighting
Q2 2019$56,000
-64.8%
116,865
-1.2%
0.00%
Q1 2019$159,000
+2.6%
118,241
-13.4%
0.00%
Q4 2018$155,000
-77.1%
136,599
-44.4%
0.00%
Q3 2018$678,000
-19.8%
245,634
+3.9%
0.00%
Q2 2018$845,000
+304.3%
236,522
+248.4%
0.00%
Q1 2018$209,000
-11.4%
67,881
+81.2%
0.00%
Q4 2017$236,000
+61.6%
37,467
+135.3%
0.00%
Q1 2017$146,000
+170.4%
15,924
+18.6%
0.00%
Q4 2016$54,000
-44.9%
13,428
-47.6%
0.00%
Q3 2016$98,000
-51.7%
25,602
-41.5%
0.00%
Q1 2016$203,000
-32.1%
43,785
+46.9%
0.00%
Q4 2015$299,000
-21.1%
29,812
-41.2%
0.00%
Q3 2015$379,000
-97.9%
50,741
-86.8%
0.00%
-100.0%
Q2 2015$18,176,000
+41.1%
383,128
+9.0%
0.02%
+33.3%
Q1 2015$12,882,000
+107250.0%
351,560
+112579.5%
0.01%
Q4 2014$12,000
-94.5%
312
-98.4%
0.00%
Q1 2014$217,00019,9230.00%
Other shareholders
TETRAPHASE PHARMACEUTICALS I shareholders Q2 2019
NameSharesValueWeighting ↓
HARVEY CAPITAL MANAGEMENT INC 354,300$7,068,0002.77%
Opaleye Management Inc. 169,700$3,385,515,0002.64%
Broadfin Capital, LLC 959,247$19,137,0002.01%
Novo Holdings A/S 900,000$17,955,0001.75%
Eventide Asset Management 300,900$6,003,0000.84%
EAM Investors, LLC 152,595$3,044,0000.62%
COLUMBIA PARTNERS L.L.C. INVESTMENT MANAGEMENT 497,858$9,932,0000.51%
Granite Point Capital Management, L.P. 40,000$798,0000.40%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 450,191$8,981,0000.33%
TFS CAPITAL LLC 133,070$2,655,0000.23%
View complete list of TETRAPHASE PHARMACEUTICALS I shareholders